Marisa Wexler, MS,  senior science writer—

A European Medicines Agency (EMA) committee recommended that Darzalex (daratumumab) given as an under-the-skin injection be approved for people with smoldering multiple myeloma (SMM)…

Most people with advanced pancreatic cancer who received first-line treatment with atebimetinib were alive and free from disease progression six months after starting treatment,…

Most people with hard-to-treat multiple myeloma who were given a combination treatment of Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) in a clinical trial were alive…

Nearly 1 in 4 people with NPM1-mutated acute myeloid leukemia (AML) achieved complete remission after treatment with ziftomenib in a Phase 2 clinical trial. Dubbed…

One-third of patients with hard-to-treat myeloma were alive and free from disease progression five years after a single infusion of the cell therapy Carvykti…

Data from a clinical trial show the experimental treatment lucicebtide has so far been well tolerated in people with glioblastoma, an aggressive type of…

A U.S. Food and Drug Administration (FDA) committee has voted in favor of Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat high-risk smoldering multiple myeloma…

BCB-276, an experimental cell therapy that Brainchild Bio is developing for diffuse intrinsic pontine glioma (DIPG), has been named a regenerative medicine advanced…

Treatment with pembrolizumab — an immune-modulating therapy sold for some cancers under the brand name Keytruda — improved survival among people with platinum-resistant ovarian cancer…

ELVN-001, an experimental treatment for chronic myeloid leukemia (CML), a type of blood cancer, is showing promising proof-of-concept effects for killing cancer cells in patients…